Special Issue

Advances in Pathogenesis and Therapeutics of Gastrointestinal Diseases

Message from the Guest Editor

This Special Issue seeks to compile cutting-edge research on the molecular and cellular mechanisms driving GI diseases, along with the latest therapeutic approaches aimed at improving patient outcomes. We invite researchers and clinicians to submit original research articles, comprehensive reviews, and case studies that address various aspects of gastrointestinal diseases, including, but not limited to:

- Molecular mechanisms and signaling pathways involved in the pathogenesis of GI diseases.
- The role of the gut microbiome in the development and progression of gastrointestinal disorders.
- Novel diagnostic biomarkers and imaging techniques for early detection.
- Advances in pharmacological treatments and targeted therapies.
- Immunological aspects and the role of inflammation in GI diseases.
- Innovative surgical techniques and their outcomes.
- The impact of diet, lifestyle, and environmental factors on GI health.

Guest Editor

Dr. Jinghua Wang

Institute of Oriental Medicine, Dongguk University, 32, Dongguk-ro, Goyang 10326, Gyeonggi-do, Republic of Korea

Deadline for manuscript submissions

31 October 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/216330

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).